Form 8-K · Current report
AppLovin 8-K, filed Aug 5, 2026
- Filed
- CIK
- 0001751008
- Accession no.
- 0001751008-26-000057
Summary
AppLovin reported second-quarter 2026 revenue of $1.924 billion, up 53% from a year earlier, with net income of $1.267 billion and Adjusted EBITDA of $1.614 billion, and guided third-quarter 2026 revenue to $2.055–$2.085 billion.
Key points
- Second-quarter 2026 revenue rose 53% to $1.924 billion, and net income rose 55% to $1.267 billion, versus $1.259 billion and $820 million respectively a year earlier.
- Basic and diluted earnings per share were $3.77 and $3.76; Adjusted EBITDA rose 58% to $1.614 billion and free cash flow was $863.3 million.
- AppLovin repurchased and withheld 1.1 million Class A shares during the quarter for a total cost of $551.3 million, leaving 335 million Class A and Class B shares outstanding.
- Third-quarter 2026 guidance is for revenue of $2.055–$2.085 billion and Adjusted EBITDA of $1.710–$1.740 billion, an 83% margin.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition On August 5, 2026, AppLovin Corporation issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein. The information in this Item 2.02 of this current report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.